anti cancer

Extensive Product Profile: Understanding Celzar 200mg Injection Celzar 200mg Injection contains Gemcitabine, an advanced nucleoside metabolic inhibitor. It is globally recognized as a cornerstone antineoplastic therapy prescribed by oncologists worldwide to target, manage, and treat various aggressive forms of solid tumor malignancies. 1. Clinical Indications & Usage Metastatic Breast Cancer: Administered in combination with Paclitaxel as a first-line intervention for patients with metastatic breast cancer after failure of prior anthracycline-based adjuvant chemotherapy. Advanced Non-Small Cell Lung Cancer (NSCLC): Utilized in combination with Cisplatin as first-line treatment for patients with inoperable, locally advanced, or metastatic NSCLC. Ovarian Cancer: Deployed in combination with Carboplatin for the treatment of patients with advanced epithelial ovarian cancer that has recurred at least 6 months after completion of platinum-based therapy. 2. Mechanism of Action: How Celzar Works DNA Synthesis Inhibition: The diphosphate metabolite inhibits ribonucleotide reductase, reducing the cellular pool of essential deoxyribonucleoside triphosphates required for DNA repair and replication. Enzyme Mimicry: As a nucleoside analogue, Gemcitabine is metabolized intracellularly by nucleoside kinases into active diphosphate (dFdCDP) and triphosphate (dFdCTP) nucleosides. 3. Administration and Dosing Guide Administration Route: Intravenous (IV) infusion only. It must be prepared by clinical personnel and infused over a strictly monitored period (typically 30 minutes). Altering infusion duration beyond recommended limits can spike toxicities. Clinical Monitoring: Routine baseline assessments and pre-dose evaluations of liver function, kidney function, and absolute blood counts are mandatory before initiating every individual treatment cycle. 4. Safety, Side Effects, and Monitoring Bone Marrow Suppression: Severe myelosuppression (anemia, leukopenia, and thrombocytopenia) is the primary dose-limiting toxicity. Absolute neutrophil counts (ANC) and platelet numbers must be reviewed prior to every infusion. Pulmonary Toxicity: Serious cases of respiratory adverse drug reactions, such as pulmonary edema, interstitial pneumonitis, or Adult Respiratory Distress Syndrome (ARDS), have been reported. Development of a new cough or unexplained dyspnea warrants immediate suspension of the drug. Common Side Effects: Nausea, vomiting, elevated liver transaminases (ALT/AST), transient proteinuria, mild hematuria, alopecia, flu-like symptoms (fever, chills, headache), rash, and peripheral edema. 5. Storage and Handling Specifications Storage Environment: Prior to reconstitution, the dry powder vial must be stored at a stable room temperature below 30°C (86°F). Precautions: Do not freeze the unreconstituted or reconstituted product, as crystallization can occur. Store within the original outer box to block direct UV light or heavy ambient moisture degradation. Keep strictly safe from children and pets. PRESCRIPTION MEDICINE IS : YES Disclaimer: Celzar 200mg Injection is a specialized prescription oncology drug that must only be administered under the direct clinical guidance and physical supervision of a registered medical oncologist in an authorized treatment setting. This information is meant strictly for educational research purposes. Celzar is highly toxic to fetal development; strict non-hormonal contraceptive methods must be pursued during therapy, and breastfeeding is completely contraindicated. 📞 Contact PRIMECARE IMPEX — Pharmaceutical Exporter from India [GROUP OF PRIME CARE IMPEX PVT. LTD.] 🌐 Corporate Website: www.medicineexporterfromindia.com 📧 Commercial Email: exports@ernestpharmaceuticals.com 📦 Business Entity Type: International Exporter | Bulk Supplier | Global Distributor 📲 Direct WhatsApp Line: +91 9673008130 🔗 https://wa.me/919673008130

Global Patient & Clinician Guide: Celvestrant 250 mg PFS Injection Celvestrant 250 mg Pre-Filled Syringe (PFS) contains Fulvestrant, an advanced, selective antineoplastic estrogen receptor antagonist. Manufactured to meet rigorous global standards by Celon Laboratories Ltd., it serves as a critical endocrine (hormone) therapy used worldwide to manage advanced, hormone-dependent malignancies. 1. Clinical Indications & Usage Hormone Receptor-Positive (HR+) Advanced Breast Cancer: Used as a single agent (monotherapy) to treat postmenopausal women with hormone receptor-positive, locally advanced, or metastatic breast cancer that has progressed following prior anti-estrogen therapy. HR+/HER2-Negative Metastatic Breast Cancer (Combination Therapy): Indicated for use in combination with CDK4/6 inhibitors (such as palbociclib, ribociclib, or abemaciclib) or other targeted anti-cancer agents for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in women. 2. Mechanism of Action: How Celvestrant Works Estrogen Receptor Binding: Fulvestrant functions as a competitive estrogen receptor antagonist, directly attaching to estrogen receptors inside the breast cancer cells with high affinity. Receptor Down-regulation: Beyond simply blocking the receptor, it alters the structural shape of the receptor, causing the cell to degrade it. This process down-regulates (reduces the overall number of) available estrogen receptors over time. Halting Proliferation: By depriving the tumor cells of essential estrogenic signaling pathways, Celvestrant prevents the transcription of estrogen-dependent genes, effectively slowing or stopping the growth and spread of the cancer. 3. Administration and Dosing Guide Administration Route: Celvestrant is strictly formulated for intramuscular (IM) injection into the gluteal muscle (buttock). It must never be given intravenously, subcutaneously, or taken orally. Administration Protocol: The solution must be injected slowly over 1 to 2 minutes by a qualified medical professional. A standard full dose is typically split into two separate 250 mg pre-filled syringes (one slow injection into each buttock). Standard Schedule: The standard adult dosing regimen begins with a loading phase to achieve steady therapeutic levels quickly, followed by maintenance dosing: Day 1: Initial 500 mg dose (two 250 mg injections). Day 15: Second 500 mg loading dose. Day 29: Third 500 mg dose. Maintenance Phase: 500 mg administered once every 28 days thereafter. 4. Safety, Side Effects, and Clinical Monitoring Injection Site Reactions: Due to the volume and intramuscular nature of the medication, localized pain, swelling, transient inflammation, sciatica, or bruising at the injection site are among the most common physical reactions. Bleeding Risks: Caution must be exercised if a patient has an underlying bleeding disorder or is taking systemic anticoagulants (blood thinners), due to the physical risk of deep muscular hematoma from the intramuscular injection. Common Side Effects: Hot flashes, generalized fatigue (weakness), nausea, vomiting, decreased appetite, joint and bone pain (musculoskeletal pain), back pain, headache, diarrhea, constipation, urinary tract infections, and skin rashes. 5. Storage and Handling Specifications Environmental Protection: Keep the pre-filled syringes securely enclosed in their original manufacturer carton to protect the solution from direct light exposure and excessive moisture. Temperature Management: Celvestrant 250 mg PFS must be stored in a secure refrigerator between 2°C and 8°C (36°F to 46°F). It must never be allowed to freeze. Safety Precaution: Store strictly out of sight and reach of children and domestic animals. Clinical Disclaimer: This comprehensive profile is compiled strictly for educational, scientific research, and informational purposes. Celvestrant 250 mg PFS Injection is a highly specialized oncology prescription medicine. It must be administered exclusively by a trained healthcare professional (doctor or nurse) in a clinical setting. Self-administration is strictly prohibited. PRESCRIPTION MEDICINE: YES 📞 Contact PRIMECARE IMPEX — Pharmaceutical Exporter from India [A Group of Prime Care Impex Pvt. Ltd.] 🌐 Corporate Website: www.medicineexporterfromindia.com 📧 Commercial Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Global Distributor 📲 Direct WhatsApp Line: +91 9673008130 🔗 Instant Chat Access: https://wa.me/919673008130

Product Profile: Celplat 50mg Injection Celplat 50mg Injection contains Cisplatin, an advanced, gold-standard platinum-based alkylating antineoplastic agent. Formulated to the highest global pharmaceutical benchmarks by Celon Laboratories Ltd., this high-strength cytotoxic injection is widely prescribed by oncology specialists globally to treat aggressive, advanced solid tumors and mutation-specific malignancies. 1. Clinical Indications & Usage Advanced Testicular Cancer: Deployed as established first-line combination therapy for patients with advanced or metastatic testicular germ cell tumors who have already undergone appropriate surgical resection or radiation. Advanced Ovarian Cancer: Indicated as primary combination therapy with other approved chemotherapeutic agents, or as single-agent systemic treatment, for patients with advanced or recurrent ovarian malignancies who have previously received platinum-based therapies. Squamous Cell Head and Neck Cancers: Administered as a potent radiosensitizer alongside radiotherapy or systemic combinations to combat advanced epithelial tumors of the head, neck, nasopharynx, and oral cavity. 2. Mechanism of Action: How Celplat Works Aquation and Activation: Once inside the low-chloride environment of the cancer cell cytoplasm, the Cisplatin molecule undergoes activation (aquation), losing its chloride leaves to become a highly reactive, positively charged platinum complex. DNA Cross-Linking: The activated platinum complex binds directly to the cellular genetic blueprint, forming strong covalent bonds primarily at the N-7 position of guanine and adenine bases. This results in tight intra-strand and inter-strand DNA cross-links. Replication Roadblock: These heavy structural cross-links fundamentally warp the double-helix geometry of the DNA. This creates an impassable roadblock that halts replication forks, stops RNA transcription, and completely suppresses further DNA synthesis. 3. Administration and Dosing Guide Administration Route: Celplat 50mg is formulated strictly for intravenous (IV) infusion. It must be diluted in an appropriate volume of sodium chloride-containing sterile fluids and administered via a secure intravenous line. It is highly unsafe for direct push and must never be self-administered. Intensive Hydration Framework: To protect the kidneys, patients must undergo intensive intravenous pre-hydration with 1 to 2 liters of fluid infused over 8 to 12 hours before receiving the drug. Adequate hydration and high urine output must be strictly maintained for 24 hours post-infusion, often accompanied by mannitol or furosemide-induced diuresis. 4. Safety, Side Effects, and Monitoring Severe Nephrotoxicity (Kidney Damage): Dose-related and cumulative renal tubular damage is the major dose-limiting risk of Cisplatin. Comprehensive pre-dose kidney function profiles (Blood Urea Nitrogen [BUN], Serum Creatinine, and Creatinine Clearance) alongside serum electrolyte checks (Magnesium, Potassium, Calcium) are mandatory before starting every treatment cycle. Severe Ototoxicity (Hearing Damage): This medication can cause significant inner ear toxicity, manifesting as severe tinnitus (ringing in the ears), high-frequency hearing loss (4,000 to 8,000 Hz range), or occasional deafness. Audiometric testing should be performed at baseline and before every subsequent dose. 5. Storage and Handling Specifications Temperature Frame: Store Celplat 50mg vials at controlled room temperature between 15°C to 25°C (59°F to 77°F). Do not refrigerate or freeze, as low temperatures will cause the active platinum compound to precipitate out of the solution. Environmental Safeguards: Keep the vials sealed securely inside their original manufacturer packaging carton to shield the medicine from direct UV light exposure. Handle with strict cytotoxic precautions, using appropriate protective equipment, and keep entirely out of reach of children. Prescription Medicine: Yes Clinical Disclaimer: This profile is compiled strictly for informational, educational, and international sourcing transparency. Celplat 50mg Injection is a specialized oncology drug available exclusively under valid clinical prescription. It must be prepared, handled, and administered solely under the direct guidance of a registered oncology specialist in a qualified hospital or clinical infusion environment. 📞 Contact PRIMECARE IMPEX — Pharmaceutical Exporter from India [A Group of Prime Care Impex Pvt. Ltd.] 🌐 Website: www.medicineexporterfromindia.com 📧 Commercial Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Global Distributor 📲 Direct WhatsApp Line: +91 9673008130 🔗 Instant Chat Access: https://wa.me/919673008130

Product Profile: Celplat 10mg Injection Celplat 10mg Injection contains Cisplatin, an advanced, gold-standard platinum-based alkylating antineoplastic agent. Formulated to the highest global pharmaceutical standards by Celon Laboratories Ltd., this specialized chemotherapy agent is widely used by oncologists worldwide to treat and manage aggressive solid tumors and mutation-specific malignancies. 1. Clinical Indications & Usage Advanced Testicular Cancer: Used in highly effective combination regimens for patients with advanced testicular tumors who have already undergone appropriate surgical or radiotherapeutic interventions. Advanced Ovarian Cancer: Indicated as combination therapy with other approved chemotherapeutic agents or as a single agent for patients with advanced ovarian tumors who have previously received platinum-based or systemic therapies. Advanced Bladder Cancer: Deployed as a single agent or combination framework for patients with locally advanced or metastatic bladder cancer who are no longer candidates for localized surgery or radiotherapy. Head and Neck Epithelial Tumors: Administered alongside radiotherapy or systemic regimens to combat advanced squamous cell carcinomas of the head and neck. 2. Mechanism of Action: How Celplat Works DNA Cross-Linking: Once inside the cytoplasm, the active Cisplatin molecule sheds its chloride ions and binds directly to the cellular genetic blueprint. It hooks onto guanine and adenine bases, creating tight intra-strand and inter-strand DNA cross-links. Replication Roadblock: These heavy platinum cross-links fundamentally warp the double-helix structure of the DNA. This creates an unpassable block that stops replication forks and suppresses DNA synthesis. Apoptosis Induction: Because rapidly dividing cancer cells cannot repair these severe, platinum-induced structural defects, the cellular check-points trigger a distress cascade. This forces the damaged cancer cells into programmed cell death (apoptosis), halting tumor growth. 3. Administration and Dosing Guide Administration Route: Celplat 10mg is formulated strictly for intravenous (IV) infusion. It must be diluted in appropriate sterile saline lines and administered by a clinical team. It is highly unsafe for direct push and must never be self-administered. Hydration Framework: To protect kidney health, patients must receive intensive intravenous hydration with fluids (often containing mannitol) for 8 to 12 hours before the infusion, and maintain high fluid volume and urine output for 24 hours post-treatment. 4. Safety, Side Effects, and Monitoring Severe Nephrotoxicity (Kidney Damage): Cumulative and dose-related renal tubular damage is a major dose-limiting risk. Comprehensive baseline and pre-dose kidney function profiles (Blood Urea Nitrogen, Serum Creatinine, and Creatinine Clearance) are mandatory before every cycle. Ototoxicity (Hearing Impairment): This medication can cause significant inner ear damage, resulting in severe tinnitus (ringing in the ears), high-frequency hearing loss, or occasional deafness. Pre-treatment and periodic audiometric testing are highly recommended . Bone Marrow Suppression: It temporarily lowers the production of red blood cells, infection-fighting white blood cells, and platelets, increasing the risks of anemia, infections, and bleeding. Baseline and weekly Complete Blood Counts (CBC) are required. 5. Storage and Handling Specifications Temperature Frame: Store Celplat 10mg vials at controlled room temperature between 15°C to 25°C (59°F to 77°F). Do not refrigerate or freeze, as low temperatures will cause the platinum compound to precipitate out of the solution. Environmental Safeguards: Keep the vials sealed securely inside their original manufacturer packaging. Protect the medicine from direct UV light exposure. Handle with strict cytotoxic precautions and keep entirely out of reach of children. Prescription Medicine: Yes Clinical Disclaimer:This profile is compiled strictly for informational, educational, and international sourcing transparency. Celplat 10mg Injection is a specialized oncology drug available exclusively under valid clinical prescription. It must be prepared, handled, and administered solely under the direct guidance of a registered oncology specialist in a qualified clinical environment 📞 Contact PRIMECARE IMPEX — Pharmaceutical Exporter from India [A Group of Prime Care Impex Pvt. Ltd.] 🌐 Website: www.medicineexporterfromindia.com 📧 Commercial Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Global Distributor 📲 Direct WhatsApp Line: +91 9673008130 🔗 Instant Chat Access: https://wa.me/919673008130

Product Profile: Celostatin LAR 30mg Injection Celostatin LAR 30mg contains Octreotide Acetate, an advanced, long-acting synthetic octapeptide that mimics natural somatostatin. Developed under stringent international quality controls by Celon Laboratories Ltd., this specialized Long-Acting Release (LAR) injection is prescribed globally by endocrinologists and oncologists to manage neuroendocrine tumors, growth hormone disorders, and specific gastrointestinal complications. 1. Clinical Indications & Usage Acromegaly: Used for long-term maintenance therapy in adult patients who have responded adequately to or are stabilized on immediate-release subcutaneous octreotide. It helps normalize excess growth hormone (GH) and Insulin-like Growth Factor-1 (IGF-1) levels when surgical resection or radiotherapy is inappropriate or ineffective. Severe Diarrhea and Flushing associated with Metastatic Carcinoid Tumors: Deployed for the symptomatic control of severe watery diarrhea and intense skin flushing episodes linked to metastatic neuroendocrine carcinoid syndrome. Vasoactive Intestinal Peptide-Secreting Tumors (VIPomas): Indicated for the management of profuse, watery diarrhea and associated electrolyte imbalances caused by VIP-secreting pancreatic adenomas. Gastro-Esophageal Variceal Bleeding: Utilized to control acute hemorrhage and prevent re-bleeding from ruptured esophageal varices in patients with chronic liver disease or cirrhosis. 2. Mechanism of Action: How Celostatin LAR Works Somatostatin Receptor Agonism: It binds selectively and with higher potency than natural somatostatin to specific somatostatin receptors (primarily SSTR2 and SSTR5) located throughout the pituitary gland and gastrointestinal tract. Hormonal Suppression: This receptor binding strongly suppresses the excessive secretion of anterior pituitary hormones, effectively reducing circulating levels of growth hormone (GH) and thyroid-stimulating hormone (TSH). Splanchnic Vasoconstriction: To combat variceal bleeding, the active drug induces selective constriction (narrowing) of the splanchnic blood vessels. This safely limits blood inflow to the portal vein system, reducing pressure and halting active hemorrhage in the food pipe. 3. Administration and Dosing Guide Professional Administration: The injection must be prepared and delivered solely by a trained healthcare professional. It is packaged as a comprehensive kit containing a vial of octreotide microspheres, a prefilled vehicle syringe, a vial adapter, and a specialized administration needle. Standard Schedule: For acromegaly and neuroendocrine tumors, the standard clinical starting dosage is 20mg or 30mg administered once every 4 weeks (28 days) for long-term management. Dosages are adjusted symmetrically by the specialist based on therapeutic hormone levels and clinical symptom response. 4. Safety, Side Effects, and Monitoring Gallbladder and Liver Alterations: Long-term utilization inhibits gallbladder contractility and decreases bile secretion, which frequently leads to cholelithiasis (gallstone formation) or biliary sludge. Periodic ultrasound examinations of the gallbladder are clinically advised. Glucose Regulation Instability: Because octreotide suppresses the release of both insulin and glucagon, it can cause unpredictable shifts in blood sugar levels, resulting in either hypoglycemia (low blood sugar) or hyperglycemia (high blood sugar). Regular blood glucose monitoring is mandatory, especially for diabetic patients. 5. Storage and Handling Specifications Cold Chain Logistics: Store Celostatin LAR 30mg kits under strict refrigeration between 2°C to 8°C (36°F to 46°F). Do not freeze. Environmental Safeguards: Keep the kit sealed within its original manufacturer carton box to shield the light-sensitive components from direct UV light exposure. Prior to administration, the kit may be allowed to reach room temperature for roughly 30 to 60 minutes to minimize injection site discomfort, but it must be injected immediately after reconstitution. Keep entirely out of reach of children. Prescription Medicine: Yes Clinical Disclaimer: This profile is compiled strictly for informational, commercial educational research, and global sourcing transparency. Celostatin LAR 30mg Injection is a controlled, high-specialty prescription drug. It must be dispensed, reconstituted, and administered exclusively under the direct supervision of a registered endocrinologist, oncologist, or qualified gastroenterology clinician. 📞 Contact PRIMECARE IMPEX — Pharmaceutical Exporter from India [A Group of Prime Care Impex Pvt. Ltd.] 🌐 Website: www.medicineexporterfromindia.com 📧 Commercial Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Global Distributor 📲 Direct WhatsApp Line: +91 9673008130 🔗 Instant Chat Access: https://wa.me/919673008130

Product Profile: Celomide 25mg Capsule Celomide 25mg Capsule contains Lenalidomide, a highly potent small-molecule immunomodulatory agent (IMiD) with powerful anti-angiogenic and direct anti-cancer activities. Formulated under strict international pharmaceutical regulatory benchmarks by Celon Laboratories Ltd., this oral targeted therapeutic option is widely utilized by oncologists globally to manage aggressive plasma cell dyscrasias and complex bone marrow disorders. 1. Clinical Indications & Usage Multiple Myeloma (MM): Prescribed in combination with dexamethasone or as part of highly effective triplet chemotherapy combinations for adult patients with newly diagnosed or relapsed/refractory multiple myeloma. The 25mg capsule typically serves as the standard starting therapeutic dose for the active phase of 28-day treatment cycles. Myelodysplastic Syndromes (MDS): Deployed to manage transfusion-dependent anemia in patients with low- to intermediate-1-risk MDS associated with a cytogenetic anomaly known as the deletion 5q (del 5q) chromosomal defect. Mantle Cell Lymphoma (MCL): Authorized for adult patients with mantle cell lymphoma whose disease has returned, relapsed, or progressed following at least one prior intensive systemic treatment (typically including a proteasome inhibitor like bortezomib). 2. Mechanism of Action: How Celomide Works Cereblon-Mediated Degradation: The drug binds directly to Cereblon (CRBN), a substrate adapter within the intracellular E3 ubiquitin ligase enzyme network. This structural binding forces the rapid degradation of essential lymphoid transcription proteins (Ikaros and Aiolos). Immune System Modulation: By shifting these cellular pathways, Celomide generates an aggressive immune up-regulation. It dramatically triggers the activation and proliferation of the patient's native T-cells and Natural Killer (NK) cells, vastly optimizing the body's natural baseline capability to clear floating tumor populations. Direct Apoptosis Induction: It induces direct cell-cycle arrest in sensitive multiple myeloma and lymphoma cells, stopping replication and driving mutated lines into rapid programmed cell death. 3. Administration and Dosing Guide Administration Route: Celomide 25mg is strictly an oral capsule formulation. The capsule must be swallowed whole with a glass of water at the exact same time every day. It should never be chewed, crushed, split, or opened. Caregivers must avoid direct skin contact or inhalation exposure to the powder contents of damaged capsules. Cyclical Treatment Schedules: For multiple myeloma and lymphoma, the conventional starting regimen involves taking a 25mg capsule once daily on Days 1 through 21 of repeated 28-day treatment cycles, followed by a mandatory 7-day rest window (Days 22–28) to facilitate bone marrow recovery. Dosing adjustments are strictly managed by the treating oncologist. 4. Safety, Side Effects, and Monitoring Severe Bone Marrow Suppression: This medication frequently induces substantial cytopenias. This includes severe neutropenia (profound drop in white blood cells, spiking infection risks) and thrombocytopenia (low platelet counts, raising the risk of bleeding and bruising). Weekly or monthly Complete Blood Counts (CBC) are mandatory. Thromboembolic Hazards: There is an escalated risk of developing dangerous blood clots, including Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), or arterial blockages (stroke/myocardial infarction). Prophylactic blood thinners are routinely co-prescribed. Common Side Effects: Chronic fatigue, diarrhea or constipation, muscle cramps, localized skin rashes, generalized itching, nausea, headache, dizziness, and peripheral edema (fluid retention in the limbs). 5. Storage and Handling Specifications Climate Parameters: Store Celomide 25mg capsules safely below 30°C (86°F) in a dry, dark, temperature-controlled environment. Protective Shields: Keep capsules sealed tightly inside their original manufacturer packaging. Protect the medication from high ambient humidity, ambient moisture, and direct UV light exposure. Keep strictly out of reach of children and domestic pets. Prescription Medicine: Yes Clinical Disclaimer: This profile is compiled strictly for informational, educational, and international sourcing transparency. Celomide 25mg Capsule is a highly restricted, specialized oncology drug available exclusively under valid medical prescription. It must be managed, dispensed, and utilized solely under the direct guidance of a registered oncology specialist. 📞 Contact PRIMECARE IMPEX — Pharmaceutical Exporter from India [A Group of Prime Care Impex Pvt. Ltd.] 🌐 Website: www.medicineexporterfromindia.com 📧 Commercial Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Global Distributor 📲 Direct WhatsApp Line: +91 9673008130 🔗 Instant Chat Access: https://wa.me/919673008130

Product Profile: Celomide 10mg Capsule Celomide 10mg Capsule contains Lenalidomide, a structural analogue of thalidomide classified as a highly effective immunomodulatory drug (IMiD). Developed under stringent global quality benchmarks by Celon Laboratories Ltd., this oral targeted therapeutic agent plays a vital role in international oncology and hematology lines of care for managing specific plasma cell variants and bone marrow cancers. 1. Clinical Indications & Usage Multiple Myeloma (MM): Utilized either as initial induction therapy or for relapsed/refractory cases, typically combined with dexamethasone or integrated into cutting-edge triplet chemotherapy protocols. The 10mg configuration is frequently utilized for strategic maintenance cycles or individualized dose-titration phases. Myelodysplastic Syndromes (MDS): Indicated for patients with transfusion-dependent anemia due to low- or intermediate-1-risk MDS associated with a cytogenetic deletion 5q (del 5q) chromosomal mutation. Mantle Cell Lymphoma (MCL): Administered to patients with mantle cell lymphoma whose disease has progressed, relapsed, or failed to respond after at least one prior intensive systemic treatment line. 2. Mechanism of Action: How Celomide Works Cereblon Complex Binding: Celomide targets and binds directly to Cereblon (CRBN), a vital part of the intracellular E3 ubiquitin ligase enzyme network. This binding prompts the selective degradation of lymphoid-specific transcription proteins (Ikaros and Aiolos). Immune System Modulation: This molecular shift stimulates a strong immune up-regulation. It dramatically enhances the activation and proliferation of the patient's native T-cells and Natural Killer (NK) cells, enhancing the body's natural capacity to destroy circulating cancer cells. Direct Anti-Angiogenesis: The active drug stops the creation of micro-vessels inside the bone marrow microenvironment by blocking vital chemical messengers, including Vascular Endothelial Growth Factor (VEGF), effectively cutting off the tumor's supply of oxygen and nutrients. 3. Administration and Dosing Guide Administration Route: Celomide 10mg is formulated strictly as an oral capsule. The capsule must be swallowed whole with water at the same time each day and must never be broken, split, crushed, chewed, or opened. Caregivers must avoid direct skin exposure to the powder contents of broken capsules. Cyclical Treatment Schedules: Dosing strategies are highly personalized according to the patient’s kidney health and blood tolerance. For instance, a common multiple myeloma cycle entails taking a 10mg capsule once daily for 21 consecutive days of a 28-day cycle, followed by a mandatory 7-day rest window to allow the bone marrow to recover. Food Affiliation: It can be taken consistently either with or without food. 4. Safety, Side Effects, and Monitoring Severe Bone Marrow Suppression: This medication frequently causes notable cytopenias, particularly severe neutropenia (profound depletion of white blood cells, heightening infection risks) and thrombocytopenia (low blood platelets, increasing the risk of bleeding and bruising). Regular baseline and periodic Complete Blood Counts (CBC) are mandatory. Thromboembolic Hazards: There is a significantly elevated risk of developing life-threatening Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), or arterial clots (stroke/myocardial infarction), especially when paired with corticosteroid therapies. Anticoagulant prophylaxis is commonly co-prescribed. Common Adverse Reactions: Patients commonly report fatigue, chronic diarrhea or constipation, localized skin rashes, muscle cramps, nausea, dizziness, headache, and peripheral edema (fluid retention in limbs). 5. Storage and Handling Specifications Climate Management: Store Celomide 10mg capsules below 30°C (86°F) in a dry, dark, climate-controlled space. Environmental Safeguards: Keep the capsules securely sealed within their original manufacturer bottle or blister packing to shield the sensitive active ingredients from high humidity, moisture, and direct UV light. Keep completely out of reach of children and pets. Prescription Medicine: Yes Clinical Disclaimer: This profile is compiled strictly for commercial educational research and international informational transparency. Celomide 10mg Capsule is a highly restricted, specialized oncology drug available exclusively under valid clinical prescription. It must be dispensed, handled, and managed solely under the direct guidance and supervision of a registered hematology-oncology specialist. 📞 Contact PRIMECARE IMPEX — Pharmaceutical Exporter from India [A Group of Prime Care Impex Pvt. Ltd.] 🌐 Website: www.medicineexporterfromindia.com 📧 Commercial Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Global Distributor 📲 Direct WhatsApp Line: +91 9673008130 🔗 Instant Chat Access: https://wa.me/919673008130

Product Profile: Celomide 5mg Capsule Celomide 5mg Capsule contains Lenalidomide, a highly effective, small-molecule immunomodulatory agent (IMiD) with specialized anti-angiogenic and direct antineoplastic activities. Manufactured under exacting global standards by Celon Laboratories Ltd., this oral targeted therapy is recognized by oncologists internationally as an integral component in management protocols for complex bone marrow disorders and hematological malignancies. 1. Clinical Indications & Usage Multiple Myeloma (MM): Prescribed in combination with dexamethasone (and frequently integrated into advanced triplet therapies) for adult patients with relapsed or refractory multiple myeloma, or deployed as an independent post-transplant maintenance therapy to prolong progression-free survival. Myelodysplastic Syndromes (MDS): Indicated for patients suffering from transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with a cytogenetic abnormality known as a deletion 5q (del 5q) chromosomal defect. Mantle Cell Lymphoma (MCL): Authorized for adult patients with mantle cell lymphoma whose disease has returned or progressed following prior systemic lines of therapy (including bortezomib). 2. Mechanism of Action: How Celomide Works Immune Modulation: Celomide binds directly to Cereblon (CRBN), a substrate adapter within the intracellular E3 ubiquitin ligase enzyme complex. This binding induces the selective degradation of crucial lymphoid transcription proteins, which up-regulates the patient's native T-cells and Natural Killer (NK) cells, enhancing their ability to recognize and kill circulating cancer cells. Direct Tumor Apoptosis: It directly stalls the cell division cycle inside mutated plasma cells and lymphoma populations, inducing intracellular stress that forces abnormal cells into programmed cell death (apoptosis). 3. Administration and Dosing Guide Administration Route: Celomide 5mg is strictly an oral capsule formulation. The capsule must be swallowed whole with a full glass of water and should never be broken, crushed, split, chewed, or opened. Caregivers must avoid inhaling or coming into direct skin contact with the powder inside damaged capsules. Food Affiliation: It can be taken consistently at the same time each day, either with or without food. Cycle-Based Schedules: Treatment plans are highly specific to the clinical indication. For instance, in a standard multiple myeloma or lymphoma cycle, a 5mg dose may be taken once daily for 21 consecutive days of a 28-day cycle, followed by a mandatory 7-day rest window to allow blood levels to recover. 4. Safety, Side Effects, and Monitoring Severe Hematological Suppression: This medication frequently causes substantial bone marrow suppression. This can result in severe neutropenia (low infection-fighting white blood cells) and thrombocytopenia (low blood platelets, increasing the risk of bruising or bleeding). Regular, baseline, and monthly Complete Blood Counts (CBC) are mandatory. Thromboembolic Events: Patients have an increased risk of developing dangerous blood clots, including Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), as well as arterial events (myocardial infarction or stroke). Prophylactic blood thinners are routinely co-prescribed. Common Side Effects: Fatigue, chronic diarrhea or constipation, muscle cramps, nausea, localized skin rashes, headache, dizziness, peripheral edema (fluid swelling in lower limbs), and upper respiratory tract infections. 5. Storage and Handling Specifications Environmental Shields: Keep capsules sealed inside their original manufacturer packaging. Protect the bottles from high ambient humidity, excessive moisture, and direct UV light exposure. Keep strictly out of reach of children and domestic pets. Temperature Protocols: Store Celomide 5mg capsules at controlled room temperature between 15°C to 30°C (59°F to 86°F) in a dark, dry location. Prescription Medicine: Yes Clinical Disclaimer: This profile is compiled strictly for informational, educational, and international sourcing transparency. Celomide 5mg Capsule is a restricted, specialized oncology drug available exclusively under valid medical prescription. It must be managed, dispensed, and utilized solely under the direct guidance of a registered oncology specialist. 📞 Contact PRIMECARE IMPEX — Pharmaceutical Exporter from India [A Group of Prime Care Impex Pvt. Ltd.] 🌐 Website: www.medicineexporterfromindia.com 📧 Commercial Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Global Distributor 📲 Direct WhatsApp Line: +91 9673008130 🔗 Instant Chat Access: https://wa.me/919673008130

Product Profile: Celnalid 25mg Capsule Celnalid 25mg Capsule contains Lenalidomide, a premier small-molecule immunomodulatory drug (IMiD) that exerts direct anti-cancer, immune-modulating, and anti-angiogenic actions. Produced under exacting global quality parameters by Celon Laboratories Ltd., this higher-strength oral targeted therapy is an essential pillar in international hematology-oncology regimens for managing aggressive plasma cell and lymphoid malignancies. 1. Clinical Indications & Usage Multiple Myeloma (MM): Implemented in initial combination regimens or relapsed/refractory treatment lines alongside Dexamethasone or as part of highly effective triplet therapies. The 25mg strength serves as the standard starting dose for the loading phase of many 28-day multiple myeloma cycles. Mantle Cell Lymphoma (MCL): Prescribed for patients with mantle cell lymphoma whose disease has relapsed or progressed after undergoing at least one prior intensive systemic treatment. Follicular Lymphoma (FL): Deployed in combination with a rituximab regimen to treat adult patients with previously treated low-grade or slow-growing follicular lymphoma. Myelodysplastic Syndromes (MDS): While lower doses are often used for maintenance, the 25mg profile remains a vital clinical tool for specific high-burden hematological disorders, including transfusion-dependent anemia caused by low-to-intermediate-risk deletion 5q (del 5q) myelodysplastic abnormalities. 2. Mechanism of Action: How Celnalid Works Cereblon Binding & Degradation: The active drug binds directly to the Cereblon (CRBN) E3 ubiquitin ligase complex. This binding alters the structural affinity of the enzyme, forcing the selective degradation of specific lymphoid transcription proteins (IKZF1 and IKZF3). Immune System Amplification: By modifying these intracellular pathways, Celnalid triggers a powerful immune up-regulation. It directly boosts the proliferation and activation of the body's native T-cells and Natural Killer (NK) cells, vastly improving their capacity to identify, hunt, and destroy floating cancer cells. 3. Administration and Dosing Guide Administration Route: Celnalid 25mg is strictly an oral capsule formulation. The capsule must be swallowed whole with a glass of water at the same time each day. It must never be chewed, crushed, split, or opened. Caregivers should avoid direct skin contact with broken or damaged capsules. Food Dynamics: It can be taken safely with or without food. Cyclical Dosing Framework: For multiple myeloma and mantle cell lymphoma, the conventional starting schedule is 25 mg taken orally once daily on Days 1 through 21 of repeated 28-day treatment cycles, followed by a mandatory 7-day rest window (Days 22–28). Oncologists may adjust dosing dynamically based on regular laboratory tolerance feedback. 4. Safety, Side Effects, and Monitoring Severe Hematological Cytopenias: The primary risk is severe bone marrow suppression. This frequently presents as deep neutropenia (profound drop in white blood cells, spiking infection risks) and severe thrombocytopenia (low platelet counts, causing bruising or abnormal bleeding). Regular, baseline, and weekly Complete Blood Counts (CBC) are standard practice during early treatment cycles. Thromboembolic Risk: There is an escalated risk of developing life-threatening Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), or arterial clots (myocardial infarction or stroke), especially when combined with steroids. Prophylactic anticoagulation therapies are routinely co-prescribed. Common Adverse Reactions: Severe fatigue, chronic diarrhea or constipation, generalized pruritus (itching), skin rashes, muscle cramps, peripheral edema (fluid swelling in limbs), nausea, and dizziness. 5. Storage and Handling Specifications Climate Controls: Store Celnalid 25mg capsules below 30°C (86°F) in a dry, temperature-controlled medical storage location. Shielding Safeguards: Keep the capsules tightly sealed within their original manufacturer packaging. Protect the medication from prolonged exposure to high ambient humidity, ambient moisture, and direct UV light. Keep completely out of the reach of children and domestic pets. Prescription Medicine: Yes Clinical Disclaimer: This profile is compiled strictly for informational, educational, and international sourcing transparency. Celnalid 25mg Capsule is a highly restricted, specialized oncology drug available exclusively under valid medical prescription. It must be handled, dispensed, and managed under the direct supervision of a registered hematologist-oncologist. 📞 Contact PRIMECARE IMPEX — Pharmaceutical Exporter from India [A Group of Prime Care Impex Pvt. Ltd.] 🌐 Website: www.medicineexporterfromindia.com 📧 Commercial Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Global Distributor 📲 Direct WhatsApp Line: +91 9673008130 🔗 Instant Chat Access: https://wa.me/919673008130

Product Profile: Celnalid 5mg Capsule Celnalid 5mg Capsule contains Lenalidomide, a potent, small-molecule immunomodulatory drug (IMiD) that also possesses distinct anti-angiogenic and direct antineoplastic properties. Manufactured by Celon Laboratories Ltd., this specialized oral targeted therapy is integrated into international oncology protocols to treat select hematological malignancies and bone marrow disorders. 1. Clinical Indications & Usage Multiple Myeloma (MM): Used extensively in combination with dexamethasone (and often a third agent) as a standard-of-care framework for adult patients with relapsed or refractory multiple myeloma, or as maintenance therapy following autologous stem cell transplantation. Myelodysplastic Syndromes (MDS): Indicated for patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with a specific chromosomal abnormality known as a deletion 5q (del 5q) cytogenetic defect. Mantle Cell Lymphoma (MCL): Prescribed for patients with mantle cell lymphoma whose disease has relapsed or progressed after at least one prior systemic therapy. Follicular Lymphoma (FL): Administered in combination with a rituximab product for adult patients previously treated for this slow-growing type of non-Hodgkin's lymphoma. 2. Mechanism of Action: How Celnalid Works Immune System Modulation: It binds directly to Cereblon (CRBN), a component of an intracellular enzyme complex. This binding triggers the selective degradation of specific transcription factors, which boosts the activity of the body's T-cells and Natural Killer (NK) cells, empowering the immune system to recognize and attack malignant cells from within. Direct Tumor Suppressing Effects: It induces cell cycle arrest and directly initiates apoptosis (programmed cell death) in susceptible cancer lines, particularly targeting abnormal plasma cells in the bone marrow. Anti-Angiogenesis: It blocks the secretion of critical chemical messengers, such as Vascular Endothelial Growth Factor (VEGF). By cutting off the signals required to grow new blood vessels, it starves the tumor of the blood supply needed to expand. 3. Administration and Dosing Guide Administration Route: Celnalid 5mg is an oral capsule formulation. Capsules must be swallowed whole with a glass of water at approximately the same time each day. They must never be broken, chewed, crushed, split, or opened. Cycle-Based Scheduling: Dosing is highly customized based on the patient's specific indication, body surface area, and kidney function. In a typical multiple myeloma regimen, a capsule is taken once daily for 21 consecutive days of a repeated 28-day cycle, followed by a 7-day rest period. Food Interactions: It can be taken consistently either with or without food. 4. Safety, Side Effects, and Monitoring Severe Hematological Toxicity: This medication causes significant bone marrow suppression. This can lead to profound neutropenia (low white blood cells, increasing severe infection risks) and thrombocytopenia (low platelets, increasing bruising and bleeding hazards). Complete Blood Counts (CBC) must be monitored weekly during the first several cycles and monthly thereafter. Thromboembolic Events: There is a significantly increased risk of developing deep vein thrombosis (DVT), pulmonary embolism (PE), myocardial infarction, and stroke—particularly when Celnalid is paired with dexamethasone. Prophylactic blood thinners are routinely prescribed. Common Adverse Reactions: Patients may experience notable fatigue, chronic diarrhea, constipation, muscle cramps, localized skin rashes, mild nausea, dizziness, and peripheral swelling (edema). 5. Storage and Handling Specifications Temperature Controls: Store Celnalid 5mg capsules at controlled room temperature between 15°C to 30°C (59°F to 86°F) in a dry location. Packaging Integrity: Keep the capsules securely sealed within their original manufacturer bottle or blister strip to shield the light-sensitive active ingredients from direct UV rays and moisture. Do not touch or handle broken capsules if you are a caregiver. Keep strictly away from children. Prescription Medicine: Yes Clinical Disclaimer:This profile is compiled strictly for commercial educational research and informational transparency. Celnalid 5mg Capsule is a specialized oncology drug available exclusively under strict clinical authorization. It must be managed, dispensed, and utilized solely under the direct guidance of a registered oncology specialist. 📞 Contact PRIMECARE IMPEX — Pharmaceutical Exporter from India [A Group of Prime Care Impex Pvt. Ltd.] 🌐 Corporate Website: www.medicineexporterfromindia.com 📧 Commercial Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Global Distributor 📲 Direct WhatsApp Line: +91 9673008130 🔗 Instant Chat Access: https://wa.me/919673008130

Carzomib 60mg Injection (Carfilzomib) – Global Patient Guide Carzomib 60mg Injection contains Carfilzomib, an advanced anti-cancer medication belonging to the class of proteasome inhibitors. It is a specialized, targeted therapy prescribed for patients navigating complex blood malignancies. 1. Clinical Indications & Usage Relapsed or Refractory Multiple Myeloma: It is prescribed for adult patients with multiple myeloma (a cancer of the plasma cells in the bone marrow) whose disease has returned (relapsed) or stopped responding (refractory) to at least one prior line of therapy. Combination & Monotherapy Protocols: Depending on the patient's individual clinical profile, Carzomib is utilized either as a standalone single agent or in highly effective combination regimens alongside other anti-myeloma medications (such as dexamethasone or lenalidomide). 2. Mechanism of Action: How Carzomib Works Proteasome Inhibition: Multiple myeloma cells produce vast quantities of abnormal proteins. Carzomib acts as a selective proteasome inhibitor, meaning it binds irreversibly to proteasomes—the cellular structures responsible for breaking down and recycling unneeded proteins. Toxic Protein Accumulation: By putting a halt to the cell's waste-disposal system, Carzomib causes a rapid, toxic buildup of proteins within the malignant plasma cells. Targeted Apoptosis: This structural overload destabilizes the cancer cells, halting their replication and forcing them into programmed cell death (apoptosis) while sparing a significant portion of healthy tissue. 3. Administration & Dosing Framework Intravenous Infusion: Carzomib is a lyophilized (freeze-dried) powder that must be carefully reconstituted and administered exclusively as an intravenous (IV) infusion by a qualified healthcare professional. It must never be self-administered. Cycle-Based Schedules: Treatment is typically given in 28-day clinical cycles. A standard protocol often involves administering the infusion 2 days a week for 3 consecutive weeks, followed by a 12-to-13-day rest period in week 4 to allow body systems to recover. Hydration Protocol: Maintaining exceptional hydration is critical. Patients are strongly advised to drink extra fluids before and during treatment to protect kidney function and ease the elimination of cellular waste. 4. Safety, Side Effects, and Monitoring Blood Count Suppression: It can lower essential blood cell counts. Regular monitoring is required to manage risks of anemia (low red blood cells causing fatigue), thrombocytopenia (low platelets increasing bruising/bleeding risks), and neutropenia (low white blood cells increasing infection vulnerability). Organ & System Vigilance: Due to how the drug is processed, regular laboratory tests are performed to monitor liver enzymes, kidney function (creatinine levels), and blood pressure. Doctors also keep a close watch on cardiac and pulmonary health. Tumor Lysis Syndrome (TLS): Because the injection destroys cancer cells rapidly, patients are monitored for TLS—a condition where cell contents flood into the bloodstream, requiring proactive hydration and medical management. Common Side Effects: Fatigue, nausea, temporary fever (pyrexia), diarrhea, headache, mild shortness of breath, and muscle spasms. 5. Storage and Handling Refrigerated Storage: Unopened vials of Carzomib 60mg must be stored under strict refrigeration between 2°C to 8°C (36°F to 46°F). Environmental Controls: Do not freeze the medication. Keep the vial sealed within its original carton to protect the contents from direct light exposure. Prescription Medicine: Yes Important Clinical Disclaimer This profile is compiled strictly for commercial educational research and informational transparency. Carzomib 60mg Injection is a specialized oncology drug available exclusively under clinical authorization. It must be dispensed and administered solely under the direct guidance and supervision of a registered oncology specialist in a hospital or clinic setting. 📞 Contact PRIMECARE IMPEX — Pharmaceutical Exporter from India [A Group of Prime Care Impex Pvt. Ltd.] Your trusted pharmaceutical exporter, bulk supplier, and international distributor supplying the USA, UK (Bristol), Australia (Sydney), Saudi Arabia (Riyadh), and UAE (Abu Dhabi). 🌐 Corporate Website: www.medicineexporterfromindia.com 📧 Commercial Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Global Distributor 📲 Direct WhatsApp Line: +91 9673008130 🔗 Instant Chat Access: https://wa.me/919673008130

Understanding Carfizome 60mg Injection (Carfilzomib) Carfizome 60mg Injection contains Carfilzomib, an advanced anti-cancer medication belonging to a class of drugs called proteasome inhibitors. It is widely prescribed globally to treat adult patients fighting complex blood cancers. Clinical Indications & Common Uses Relapsed or Refractory Multiple Myeloma: A type of bone marrow cancer affecting plasma cells. It is used when the disease has returned or stopped responding to previous therapies. Combination Treatment Support: Frequently administered alongside other oncology medications (such as Dexamethasone or Lenalidomide) to increase overall effectiveness. How Carfizome Works Cancer cells rely heavily on internal “recycling centers“ called proteasomes to break down waste proteins and survive. Carfizome works by binding to and blocking these proteasomes. This causes toxic waste proteins to accumulate rapidly inside the malignant cells, ultimately triggering their destruction while sparing most healthy cells. Administration & Storage Route: This medication is strictly administered as a controlled intravenous (IV) infusion into a vein by a qualified healthcare professional in a hospital or specialized clinic. Do not attempt to self-administer. Storage: Store under refrigerated conditions between 2°C and 8°C (36°F to 46°F). Do not freeze, and protect the vial from direct light. 📄 Clinical Disclaimer & Safety Notes Carfizome 60mg Injection is a highly potent prescription-only oncology medication. It must be administered exclusively under the direct supervision of a registered oncologist. Common side effects can include fatigue, nausea, fever, shortness of breath, and low blood cell counts. This medication can cause serious fetal harm; effective contraception is mandatory for both male and female patients during treatment. 📞 Contact PRIMECARE IMPEX — Pharmaceutical Exporter from India [A Group of Prime Care Impex Pvt. Ltd.] Your trusted pharmaceutical exporter, bulk supplier, and international distributor supplying the USA, UK (Bristol), Australia (Sydney), Saudi Arabia (Riyadh), and UAE (Abu Dhabi). 🌐 Corporate Website: www.medicineexporterfromindia.com 📧 Commercial Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Global Distributor 📲 Direct WhatsApp Line: +91 9673008130 🔗 Instant Chat Access: https://wa.me/919673008130